Biotinylated Anti-Rituximab Antibodies (recommended for PK/PD) (RIB-BY35c) is expressed from human 293 cells (HEK293).
Recognizes Rituximab specifically, no cross reactivity with other humanized antibodies.
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A specially optimized long-spacer biotin reagent (13.5 angstroms) is used in this product to minimize potential steric hindrance.
The biotin to protein ratio is 1-3 as determined by the HABA assay.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 years under sterile conditions after reconstitution.
Biotinylated Anti-Rituximab Antibodies (recommended for PK/PD) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Detection of Rituximab by ELISA in serum. Immobilized Anti-Rituximab Antibodies (recommended for PK/PD) (Cat. No. RIB-Y37) at 1 μg/mL, added increasing concentrations of Rituximab (10% human serum) and then added Biotinylated Anti-Rituximab Antibodies (recommended for PK/PD) (Cat. No. RIB-BY35c) at 1 μg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 12 ng/mL.
Immobilized Rituximab at 1 μg/mL (100 μL/well) can bind Biotinylated Anti-Rituximab Antibodies (recommended for PK/PD) (Cat. No. RIB-BY35c) with a linear range of 0.39-25 ng/mL.
Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids